Neurogenic compounds

• US 20080227829A1
• Filed: 02/13/2008
• Published: 09/18/2008
• Est. Priority Date: 02/14/2007
• Status: Abandoned Application

• Current Assignee: Mars Incorporated, Salk Institute for Biological Studies
• Original Assignee: Mars Incorporated
• Inventors: Gage, Fred H., Kelm, Mark A., van Praag, Henriette, Hammerstone, John F.
• Application Number:
  US12/069,861
• Publication Number:
  US 20080227829A1
• Time in Patent Office: Days
• US Class Current: 514/350
• CPC Class Codes: A61K 31/35 having six-membered rings with one oxygen as the only ring hetero atom
• CPC Class Codes: A61K 31/44 Non condensed pyridines; Hydrogenated derivatives thereof
• CPC Class Codes: A61K 31/70 Carbohydrates; Sugars; Derivatives thereof sorbitol A61K31/047
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/24 Antidepressants
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The invention relates to method(s) of use of the compound(s) described herein, e.g. method for stimulating neurogenesis, including in vitro neurogenesis, by contacting neuronal progenitor cells with an effective amount of the compound(s) described herein; method for treatment of a subject in need of treatment with a neurogenic compound; and/or for treatment of a disease or condition associated with damage to the hippocampus. The subject may be a human or a veterinary animal.

Claims

1. A method of treating a subject in need of treatment with a neurogenic compound comprising administering to the subject an effective amount of at least one compound selected from the group consisting of:

a compound of formula I, a compound of formula II, a compound of formula III, a compound of formula IV, a compound of formula V, a compound of formula VI, and a pharmaceutically acceptable salt of each;

2. The method of claim 1, wherein the subject is a human.

3. The method of claim 2, wherein the compound is administered in combination with exercise.

4. The method of claim 2, wherein the human is other than the one suffering from a neurodegenerative disease.

5. The method of claim 3, wherein the human is other than the one suffering from a neurodegenerative disease.

6. The method of claim 2, wherein the human is an elderly human.

7. The method of claim 3, wherein the human is an elderly human.

8. The method of claim 6, wherein the elderly human is a healthy elderly human.

9. The method of claim 7, wherein the elderly human is a healthy elderly human.

10. The method of claim 2, wherein the human suffers from an early stage Alzheimer'"'"'s Disease.

11. The method of claim 2, wherein the human suffers from a disease or condition associated with damage to the hippocampus.

12. The method of claim 2, wherein the compound is administered without exercise.

14. The method according to claim 2, wherein the human suffers from depression and/or post-traumatic stress disorder.

15. The method according to claim 2, wherein the human suffers from anterograde amnesia and/or retrograde amnesia.

16. The method according to claim 2, wherein the human suffers from navigation disorientation.

17. The method according to claim 2, wherein the human is a soldier or combatant.

13. A method of stimulating neurogenesis comprising contacting a neural progenitor cell with an effective amount of a compound selected from the group consisting of at least one compound of formula I, a compound of formula II, a compound of formula III, a compound of formula IV, a compound of formula V, a compound of formula VI, and a pharmaceutically acceptable salt of each: